Ratings
0
Nobody has rated this yet. Be the first!
Works
3
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation
